

AD_____

Award Number: DAMD17-97-1-7260

TITLE: The Role of SHP1 as a Tumor Suppressor in Human Mammary
Tumorigenesis

PRINCIPAL INVESTIGATOR: Muling Mao

CONTRACTING ORGANIZATION: The University of Texas
M.D. Anderson Cancer Center
Houston, Texas 77030

REPORT DATE: August 2000

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentat

20030227 069

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2000	3. REPORT TYPE AND DATES COVERED Final (1 Aug 97 - 31 Jul 00)	
4. TITLE AND SUBTITLE The Role of SHP1 as a Tumor Suppressor in Human Mammary Tumorigenesis			5. FUNDING NUMBERS DAMD17-97-1-7260	
6. AUTHOR(S) Muling Mao				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030 E-MAIL: mmao@gsbs3.gs.uth.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) SHP-1, the Src homology 2-containing protein tyrosine phosphatase 1, involves in the dephosphorylation of growth factor-receptors or non-receptor protein tyrosine kinases and serves as a negative regulator of proliferative signaling in cells. In addition, PI3K signaling pathway plays an important role in growth factor-mediated cell survival and proliferation. To investigate the regulation of PI3K signaling in malignant epithelial cells, we studied the interaction of SHP-1 with multiple mediators in the cascade, including PI3K, PTEN and AKT. In SKBr3 cells, we observed a growth factor-stimulation induced association of SHP-1 with PTEN. Further study revealed that binding of SHP-1 to PTEN was enhanced by LCK, a Src family tyrosine kinase, suggesting a tyrosine phosphorylation-mediated interaction between the two proteins. In order to investigate the regulation of SHP-1 on PTEN, we coexpressed wild type SHP-1 or inactive mutant SHP-1 with PTEN in cells. Our data showed that functional SHP-1 decreased LCK-induced tyrosine phosphorylation of PTEN, indicating the modulation of SHP-1 on PTEN function. Consistent with the modulation of SHP-1 on PI3K pathway components, we observed a functional SHP-1-dependent decrease in PI3K activity. In addition, our result indicated a dramatic physical association of two major effectors downstream of PI3K, AKT and PKC ζ in breast cancer cells. It also clearly showed that PKC ζ negatively regulated growth factor-induced AKT phosphorylation in PI3K signaling, suggesting a complicated interaction of many proteins in the pathway.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 24	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	6
Key Research Accomplishments.....	10
Reportable Outcomes.....	11
Conclusions.....	13
References.....	14
Appendices.....	16

Introduction

The Src homology 2 (SH2)-containing protein tyrosine phosphatase 1, SHP-1, is highly expressed in many non-hematopoietic cells, especially in some malignant epithelial cells, where it generally functions as a negative regulator of proliferative signaling [1,2]. Consistent with its role of down-regulating receptor-mediated cellular processes, the phosphatase activity of SHP-1 has been shown to dephosphorylate and regulate protein tyrosine kinases such as epithelial growth factor receptor (EGFR) and Src family members in human cancer cells [3,4].

Our studies of a murine model lacking SHP1 implicated SHP1 in the development of breast cancer. Extension of these studies by Dr. Gao to breast cancer cells indicated that introduction of wild type but not dominant negative SHP1 into human breast cancer cells decreased growth of the breast cancer cells in vitro and in vivo. These studies lead to the successful completion of a PhD by Dr. Chuan Gao. This suggested that the role of SHP1 in the development of breast cancer may be complex. At this time, it became clear that the breast cancer tumor suppressor gene PTEN regulated the PI3K pathway in human tumor cells. Further, we demonstrated that PTEN and the PI3K pathway played critical roles in the regulation of cell proliferation as well as cell survival through apoptosis and anoikis. With the permission of the DoD, Muling Mao, a PhD student, continued the studies initiated by Chuan Gao and explored the role of SHP1 and the PTEN/PI3K signaling pathway in breast cancer tumorigenesis. This led to five manuscripts published or in press directly on this interaction, one abstract and seven manuscripts on phospholipid growth factors in the related disease ovarian cancer.

One important protein that is implicated in growth factor receptor-mediated cell survival in malignant mammary epithelial cells is phosphatidylinositol 3-kinase (PI3K) [5]. PI3K consists of a p85 regulatory subunit, which can be tyrosine-phosphorylated and associates with SH2 domain-containing proteins, and a p110 catalytic subunit, which phosphorylates the 3'-hydroxyl of the inositol ring of phosphatidylinositol [5,6]. The PTEN tyrosine phosphatase, which is the cause of the Cowden's breast cancer predisposition syndrome, directly dephosphorylates the same site in the inositol ring of phosphatidylinositol phosphorylated by PI3K. Further the AKT2 and AKT3 targets of PI3K are amplified in

breast cancer and in breast cancer independent of estrogen stimulation, respectively. Thus the PI3K pathway is a critical regulator of breast tumorigenesis.

Activation of PI3K leads to stimulation of multiple effectors, such as PDK1, AKT, GSK3, p70 S6K and PKC ζ [7,8,9], and can in turn be involved in cell survival as well as anti-apoptotic signaling [10]. Many lines of evidence have shown that the PTEN/PI3K pathway plays a critical role in the development of human breast cancer by providing survival signaling. However, the role of the interaction of SHP-1 with PI3K in breast tumorigenesis is still not clear. One molecule that is closely related to PI3K-mediated breast tumorigenesis is a tumor suppressor gene, namely PTEN. PTEN serves as a negative regulator of signaling cascade through PI3K by dephosphorylating position D3 of phosphatidylinositol (3,4,5) triphosphate, the direct product of PI3K [11]. Enforced expression of PTEN is reported to cause decreased cell proliferation and decreased tumorigenicity [12]. The mechanism of PTEN-regulated alterations in cell growth and survival in breast cancer cells is not clear. PKC ζ , belonging to the atypical subfamily of PKCs, is also an important component in PI3K pathway and involved in cellular responses induced by some growth factors [13,14]. PKC ζ is regulated by the PTEN/PI3K pathway and as demonstrated below regulates the PI3K pathway in a feedback mechanism. The positive or negative regulation of PKC ζ on signaling through PI3K needs to be further investigated.

In this report, in order to elucidate the interaction of the protein mediators, including SHP-1, AKT, PTEN and PKC ζ , in the PTEN/PI3K signaling pathway and their potential roles in PTEN/PI3K-related mammary tumorigenesis, we investigate the physical and functional associations of these molecules in breast cancer cells and other cell lines.

Body

1. The expression and activity of SHP1 in human breast cancer cells.

The expression levels of SHP1 in a series of human breast cancer cell lines were determined by Western blotting analysis. In comparison to normal human breast epithelium and two nontumorigenic human breast epithelial cell lines, MCF 10A and 10F, most of the human breast cancer cell lines showed normal or slightly elevated levels of SHP1 expression, with the exceptions of the cell lines MDA-MB231 and MDA-MB435, which showed very low or undetectable levels of SHP1 expression, respectively.

The activity levels of SHP1 in these human breast cancer cell lines were determined in assays using PNPP as substrate following immunoprecipitation with anti-SHP1 antibody. The assay results showed that the levels of SHP1 activity in these cell lines corresponded with their levels of expression. No altered specific activity was found.

2. Stable over-expression of SHP1 in the MDA-MB231 human breast cancer cells.

SHP1, or an enzymatically inactive form of SHP1 was transfected into both the MDA-MB231 and MDA-MB435 cells using LipofectAmine reagent. Upon selection of stably transfected clones with G418, only the MDA-MB231 cells yielded numerous clones with SHP1 expression, whereas transfection of the MDA-MB435 cells failed to yield any clones with increased SHP1 expression in several attempts.

3. The effects of SHP1 when stably over-expressed in the MDA-MB231 cells.

A. The effects of SHP1 over-expression on proliferation rate.

The proliferation rates of the MDA-MB231 clones stably transfected with either vector alone, SHP1, or the inactive form of SHP1 were determined by the means of MTT assays. The results showed no significant difference in growth rates among all clones in vitro.

B. The effects of SHP1 over-expression on anchorage-independent growth.

The ability of the MDA-MB231 clones to grow in an anchorage-independent manner was determined by soft agar assays. The results showed that the over-expression

of enzymatically active SHP1 in the MDA-MB231 cells led to increased anchorage-independent growth, whereas the vector or the enzymatically inactive form of SHP1 failed to do so.

C. The effects of SHP1 over-expression on tumorigenicity in nude mice.

The tumorigenicity of the MDA-MB231 clones was determined in nude mice by injections of the cells in the mammary fat pad. The sizes of the tumors were measured over a period of two months. The results showed that only enzymatically active SHP1 rendered the cells increased tumorigenicity, while neither the vector nor the inactive form of SHP1 had any clear effects.

D. The effect of wt SHP1 overexpression on tumorigenicity

Cells (1×10^6 of each cell line, including the parental cells MDA-MB231 and the stable transfectants) were injected into the mammary fat pad of a group of five 6-8 week old female nude mice. Tumor progression was monitored twice a week and followed for up to 7-8 weeks after the injection. The transfectants expressing wt SHP1, but not dn SHP1, produced larger tumors than the parental cells and the pcDNA3 (neo) transfectants.

To rule out the potential influence of clonal variation, a similar yet not identical experiment was also conducted to study the effect of SHP1 on tumorigenicity. In this experiment, the pooled clones of the MDA-MB231 cells stably transfected with either the vector pcDNA3 (neo), wt SHP1, or dn SHP1, instead of the individually selected clones, were injected into nude mice. Again, wt SHP1 pooled clone produced large tumors, whereas the pooled neo clone and dn SHP1 clone produced smaller, similar sized tumors.

Based on the results of these experiments, we concluded that overexpression of SHP1 in the MDA-MB231 cells led to enhanced tumorigenicity and that the enzymatic activity of SHP1 was crucial for such a positive effect.

4. Growth factor stimulation induces PTEN association with SHP1 in SKBr3 cells.

We coexpressed PTEN and SHP1 in SKBr3 breast cancer cells either unstimulated or stimulated with insulin, EGF or PDGF respectively. Western blotting with anti-SHP1 antibody indicated that SHP1 was readily detected in PTEN-immunoprecipitates from cells stimulated with growth factors.

5. LCK induces tyrosine phosphorylation and protein association between PTEN and SHP1 in COS7 cells.

To investigate the nature of the association between SHP1 and PTEN, we exploited phosphatase activity-deficient mutants, SHP1 (C453S) and PTEN (C124S) to exclude autodephosphorylation of the two proteins. Our result showed that introduction of LCK, a Src family tyrosine kinase, induced a dramatic increase in association of PTEN (C124S) with SHP1 (C453S) in COS7 cells, suggesting a tyrosine phosphorylation-related interaction between the two molecules.

6. SHP1 decreases LCK-induced tyrosine phosphorylation of PTEN.

Since PTEN negatively regulates PI3K signaling by altering the production of phosphatidylinositol (3,4,5) triphosphate and PTEN is physically bound to SHP1, we investigated the potential regulatory effect of SHP1 on PTEN. Our data showed that wild type SHP1, but not inactive mutant SHP1 (C453S), decreased LCK-induced tyrosine phosphorylation of PTEN, indicating the contribution of SHP1 to signaling through PI3K pathway. Tyrosine phosphorylation of PTEN leads to inactivation of PTEN functional activity and directs PTEN to proteasome mediated degradation. Thus the role of SHP1 in reversing PTEN tyrosine phosphorylation plays a major role in PTEN function.

7. SHP1 decreases PI3K activity.

In order to explore whether SHP1 contributes to the regulation of PI3K itself, we coexpressed SHP1 and HA-tagged p85 into Cos7 cells and detected kinase activity of PI3K. The result showed a functional SHP1-dependent decrease in PI3K activity, suggesting that SHP1 negatively regulates PI3K itself and potentially modulates activity of downstream effectors in PI3K pathway. This was mediated at least in part by the ability of SHP1 to dephosphorylates tyrosine 688 in the p85 regulatory subunit of PI3K.

8. PKC ζ associates with AKT in an EGF-dependent manner.

Reports from other groups indicate that PKC ζ , a major component downstream of PI3K, is involved in cellular signaling by regulating p70 S6K and other proteins. In order to investigate the contribution of PKC ζ to PI3K-mediated signaling and its potential

role in tumorigenesis, we detected the interaction between PKC ζ and AKT, a major effector of PI3K, in breast cancer cells.

We immunoprecipitated AKT from BT-549 cells either unstimulated or stimulated with 20ng/ml EGF, and examined the presence of PKC ζ in the precipitate. The result showed that PKC ζ physically associated with AKT in an EGF-dependent way.

9. PKC ζ down-regulates EGF-induced AKT phosphorylation.

We coexpressed epitope-tagged PKC ζ and AKT into BT-549 cells. After starvation for over night, cells were lysed following stimulation with 20ng/ml EGF. Western blotting with anti-phospho-AKT antibodies at Ser473 or Thr308 showed that overexpression of PKC ζ inhibited phosphorylation of AKT induced by EGF, suggesting a negative modulation of PKC ζ on AKT, a major effector of PI3K. This result indicates that besides PTEN and SHP1-mediated negative regulations on PI3K signaling PKC ζ , to an extent, contributes to regulate signaling downstream of PI3K.

FUTURE STUDIES

Based on the interactions between SHP1 and PTEN and the PI3K pathway, we have expressed PTEN in breast epithelium under the MMTV promoter and are presently characterizing the mice.

Key Research Accomplishments

- 1. In MDA-MB231 human breast cancer cells, the over-expression of wild type SHP1 but not catalytically inactive dominant negative SHP1 did not alter cell proliferation rate under anchorage dependent conditions.**
- 2. In MDA-MB231 breast cancer cells, the over-expression of wild type SHP1 but not catalytically inactive dominant negative SHP1 resulted in increased anchorage-independent growth.**
- 3. In MDA-MB231 breast cancer cells, the over-expression of wild type SHP1 but not catalytically inactive dominant negative SHP1 resulted in increased tumorigenicity in nude mice.**
- 7. Expression of wild type but not dominant negative SHP1 increases growth of breast cancer cells in vitro and in vivo.**
- 8. Growth factor stimulation induces PTEN association with SHP1 in SKBr3 breast cancer cells.**
- 9. LCK induces tyrosine phosphorylation and protein association between PTEN and SHP1 in COS7 cells.**
- 10. SHP1 decreases LCK-induced tyrosine phosphorylation of PTEN.**
- 11. SHP1 decreases PI3K activity.**
- 12. PKC ζ associates with AKT in breast cancer cells in an EGF-dependent manner.**
- 13. PKC ζ down-regulates EGF-induced AKT phosphorylation.**

Reportable Outcomes

1. Chuan Gao, who has been supported by this award since August 1997, received a Ph.D. degree in August 1999.
2. Lu, Y., Lin, Y., Lapushin, R., Cuevas, B., Fang, X., Yu, S., Davies, M., Khan, H., Furui, T., Mao, M., Zinner, R., Hung, M-C, Steck P., Siminovitch K., and Mills G.B. 1999 The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. *Oncogene*: 18 (50): 7034-45.
3. Furui, T., LaPushin, R., Mao, M., Kahn, H., Watt, S.R., Watt, M.V., Lu, Y., Fang, X.J., Tsutusi, S., Siddik, Z., Bast, R., and Mills G.B. 1999 Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid independent manner. *Clinical Cancer Research*: 5:4308-4318.
4. Pustilnik, T.B., Estrella, V., Wiener, J., Mao, M., Eder A., Watt, M.A.V. , Bast, R., and Mills, G.B. 1999. Lysophosphatidic acid induces urokinase secretion in ovarian cancer cells. *Clinical Cancer Research*: 5:3704-10.
5. Fang, X.J., Yu, S., Eder, A., Mao, M., Bast, R.C., Boyd, D., and Mills G.B., 1999 Regulation of BAD phosphorylation at serine 112 by the Ras-Mitogen-activated protein kinase pathway. *Oncogene*: 18:6635-6640
6. Eder, A., Sasagawa, T., Mao, M., Aoki, J., Mills, G., 2000. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: Role of phospholipase D and phospholipase A2 *Clinical Cancer Research*: 6:2482-2491
7. Fang, X-J., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Putstilnik, T., Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R., Wiener, J., Erickson, J., and Mills, G.B., 2000 Lysophospholipid growth factors in the initiation, progression, metastases and management of ovarian cancer. *Annals of the New York Academy of Science*:95:188-208.
8. Erickson, J. R., Hasegawa, Y., Fang, X., Eder, A., Mao, M., Furui, T, Aoki, J., Morris, A., and Mills G.B., 2001 Lysophosphatidic Acid and Ovarian Cancer: A

Paradigm for Tumorigenesis and Patient Management. Prostaglandins Other Lipid Mediat. 64:63-81.

9. Mills, G.,B., Fang, X., Hasegawa, Y., Eder, A., Mao, M., Tanyi, J., Tabassam, F., Yiling Lu, Furui, T., Aoki, J., and Erickson, J., 2001, Role of Lysophosphatidic Acid in the Diagnosis, Pathophysiology and Management of Ovarian Cancer: Disease Markers: In press
10. Mills, G.,B., Fang, X., Hasegawa, Y., Eder, A., Mao, M., Tanyi, J., Tabassam, F., Yiling Lu, Furui, T., Aoki, J., and Erickson, J., 2001, Critical role of Lysophospholipids in the Pathophysiology, Diagnosis, and Management of Ovarian Cancer Kluwer Press S. Stack and D. Fishman Editors In Press.
11. Mills, G.B., Lu, Y., Fang, X. Wang, H., Eder, A., Mao, M., Swaby, R., Cheng, KW. Stokoe D., Jafe, R., Gray, J., and Siminovitch K., 2001 Role of abnormalities of PTEN and the phosphatidylinositol 3' kinase pathway in breast and ovarian tumorigenesis, prognosis and therapy. Seminars in Oncology: In press
12. Cuevas, B.D., Lu. Y., Mao, M., Zhang, J., Lapushin R., Siminovitch, K., and Mills G.B. 2001 Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol Chem. In press.
13. Mao, M., Fang, X., Lu, Y., Cuevas, B., Mills G.B. 2000 PKC ζ inhibits growth factor induced phosphorylation and activity of the PKB/AKT regulator of cell viability. *Proceedings of the American Association for Cancer Research vol. 41*, pp252. Abstract
14. Mao, M., Fang, X., Lu, Y., Lapushin, R., Bast, R. C. and Mills, G.B. 2000 Inhibition of growth factor-induced phosphorylation and activation of PKB/AKT by atypical PKC in breast cancer cells. *Biochemical Journal*: 352: 475-482.

Conclusions

In this report, we clearly address that SHP1 is physically associated with lipid phosphatase PTEN (also called MMAC1) in both breast cancer cell line SKBr3 and COS7 cells. Since this interaction is dependent on various growth factors, such as insulin, EGF and PDGF, it strongly suggests the involvement of SHP1 in signaling downstream of these growth factor receptors. Based on the concept that PTEN functions as a negative controller of PI3K pathway, we have examined the effects of SHP1 on PTEN and PI3K functions. Our data indicate that SHP1 decreases PTEN phosphorylation induced by Lck and decreases PI3K activity. Therefore, the involvement of SHP1 in signaling through PI3K pathway, and consequently in mammary tumorigenesis, has been strongly suggested.

Furthermore, we have observed that two important components downstream of PI3K, AKT and PKC ζ , physically and functionally interact with each other. Described in detail, PKC ζ binds AKT in a growth factor-dependent manner and negatively regulates AKT activity. Since AKT is a major effector of PI3K to prevent cell death, these results undoubtedly implicate a role of PKC in modulating antiapoptotic signaling in cells. Although it seems unlikely that SHP1 might directly regulate AKT or PKC ζ , they obviously affect different levels in PI3K pathway to modulate cell growth and survival.

The significance of the above studies is not only because they provide valuable information on the mechanism of signaling cascades in cells but also, in a medical point of view, because they potentially indicate some tumor drug targets important in clinical application.

References

1. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. 1995 *Science* 268(5208):293-7.
2. Bittorf T, Seiler J, Zhang Z, Jaster R, Brock J. SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. 1999 *Biol Chem* 380(10):1201-9.
3. Keilhack H, Tenev T, Nyakatura E, Godovac-Zimmermann J, Nielsen L, Seedorf K, Bohmer FD. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. 1998 *J Biol Chem* 273(38):24839-46.
4. Kharitonov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. 1997 *Nature* 386(6621):181-6.
5. Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. 2000 *Biochemistry (Mosc)* 65(1):59-67.
6. Funaki M, Katagiri H, Inukai K, Kikuchi M, Asano T. Structure and function of phosphatidylinositol-3,4 kinase. 2000 *Cell Signal* 12(3):135-42.
7. Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. 1999 *J Clin Invest* 104(12):1655-61.
8. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/AKT. 1999 *Exp Cell Res* 199 253(1):210-29.
9. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. 2000 *Biochem J* 346 Pt 3:561-76.

10. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. 1999 *Exp Cell Res* 253(1):100-9.
11. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. 2000 *Biochim Biophys Acta* 1470(1):M21-35.
12. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. 2000 *Cancer Res* 60(6):1541-5.
13. Romanelli A, Martin KA, Toker A, Blenis J. p70 S6 kinase is regulated by protein kinase C zeta and participates in a phosphoinositide 3-kinase-regulated signaling complex. 1999 *Mol Cell Biol* 19(4):2921-8.
14. Mendez R, Kollmorgen G, White MF, Rhoads RE. Requirement of protein kinase C zeta for stimulation of protein synthesis by insulin. 1997 *Mol Cell Biol* 17(9):5184-92.

Appendices

One **reprint** of the paper named " Inhibition of growth factor-induced phosphorylation and activation of PKB/AKT by atypical PKC in breast cancer cells." is attached.

Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells

Muling MAO*, Xianjun FANG*, Yiling LU*, Ruth LAPUSHIN*, Robert C. BAST, JR† and Gordon B. MILLS*¹

*Department of Molecular Therapeutics, Box 317, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A., and

†Department of Translational Research, Box 92, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A.

The protein kinase B/Akt serine/threonine kinase, located downstream of phosphoinositide 3-kinase (PI-3K), is a major regulator of cellular survival and proliferation. Atypical protein kinase C (aPKC) family members are activated by PI-3K and also contribute to cell proliferation, suggesting that Akt and aPKC might interact to activate signalling through the PI-3K cascade. Here we demonstrate that blocking PKC activity in MDA-MB-468 breast cancer cells increased the phosphorylation and activity of Akt. Functional PI-3K was required for the PKC inhibitors to increase Akt phosphorylation and activation, potentially owing to the activation of specific PKC isoforms by PI-3K. The concentration dependence of the action of the PKC inhibitors implicates aPKC in the inhibition of Akt phosphorylation and activity. In support of a role for aPKC in the regulation of Akt, Akt and PKC ζ or PKC λ/ι were readily co-precipitated

from the BT-549 breast cancer cell line. Furthermore, the overexpression of PKC ζ inhibited growth-factor-induced increases in Akt phosphorylation and activity. Thus PKC ζ associates physically with Akt and decreases Akt phosphorylation and enzyme activity. The effects of PKC on Akt were transmitted through the PI-3K cascade as indicated by changes in p70 s6 kinase (p70^{s6k}) phosphorylation. Thus PKC ζ , and potentially other PKC isoenzymes, regulate growth-factor-mediated Akt phosphorylation and activation, which is consistent with a generalized role for PKC ζ in limiting growth factor signalling through the PI-3K/Akt pathway.

Key words: atypical PKC, epidermal growth factor, phosphoinositide 3-kinase, PKC inhibitor, p70^{s6k}.

INTRODUCTION

Three mammalian isoforms of protein kinase B (PKB)/Akt have been identified, termed PKB α , PKB β and PKB γ , or Akt1, Akt2 and Akt3. Akt1 and Akt2 are widely expressed in various tissues, whereas the expression of Akt3 is more restricted [1]. Akt regulates multiple biological functions including protein synthesis, apoptosis and glycogenesis [2,3]. The amplification of multiple components of the phosphoinositide 3-kinase (PI-3K) signalling cascade, including the catalytic subunit of PI-3K and Akt2 and mutational inactivation of the PTEN multifunctional phosphatase in human carcinomas, is in accordance with the importance of Akt and PI-3K in tumorigenesis [1].

The activation of Akt by growth factors is mediated, at least in part, by phosphorylation of Thr-308 in the catalytic domain and Ser-473 at the C-terminus. In many systems the phosphorylation of both Akt sites is blocked by pretreatment of the cells with the PI-3K inhibitors wortmannin or LY294002, indicating that they are phosphorylated as a consequence of PI-3K signalling [4,5]. PtdIns(3,4,5)P₃-dependent protein kinase 1 (PDK1) specifically phosphorylates Thr-308, whereas PDK-2 phosphorylates Ser-473. Ilk, PDK1 or autophosphorylation could account for the phosphorylation of Ser-473 [6–8]. PI-3K, by the generation of 3-phosphorylated PtdIns(3,4,5)P₃ and subsequent conversion into PtdIns(3,4)P₂ by SHIP, initiates a kinase cascade converging on Akt. In addition, heat shock and the activation of adenylate cyclase can modulate Akt activity by PI-3K-independent mechanisms [9]. A recent report showed that

protein kinase C ζ (PKC ζ) might negatively regulate Akt activity in a PI-3K-independent manner [10]. Thus both PI-3K-dependent and PI-3K-independent pathways might contribute to the regulation of Akt, depending on the ligand and the cell lineage analysed.

PKC is a family of structurally related serine/threonine protein kinases. The mammalian PKC isotypes have been grouped into three subfamilies, namely classical PKCs (cPKCs), novel PKCs (nPKCs) and atypical PKCs (aPKCs), on the basis of their structural and regulatory properties. PI-3K regulates aPKC, potentially through the activation of PDK1 by 3-phosphorylated phosphatidylinositols [11]. The multiple mechanisms of activation of PKC might account for the pleiomorphism and diversity of the cellular activities in which PKC has been implicated. It is also likely that specific PKC isoenzymes execute distinct cellular functions, including the regulation of anchorage-dependent and anchorage-independent growth, alterations in morphology and tumorigenicity [12–14]. The aPKC isotypes have been shown to be critically involved in cell proliferation and survival [15,16].

Here we demonstrate that PKC ζ and, to a smaller extent PKC λ/ι , physically and functionally interact with Akt. This interaction is associated with an inhibition of activation-dependent phosphorylation of Akt at both Ser-473 and Thr-308. This translates into a decrease in Akt activity and a subsequent decrease in phosphorylation at Thr-389 in p70 s6 kinase (p70^{s6k}) in intact cells. This process is PI-3K-dependent, probably as a consequence of PI-3K-dependent activation of PKC ζ . Thus the

Abbreviations used: aPKC, atypical PKC; cPKC, classical PKC; dn, dominant-negative; EGF, epidermal growth factor; HRP, horseradish peroxidase; LPA, lysophosphatidic acid; mAb, monoclonal antibody; nPKC, novel PKC; p70^{s6k}, p70 s6 kinase; PDK1, PtdIns(3,4,5)P₃-dependent protein kinase 1; PI-3K, phosphoinositide 3-kinase; PKC, protein kinase C.

¹ To whom correspondence should be addressed (e-mail: gmills@notes.mdacc.tmc.edu).

activation of PKC ζ through PI-3K serves to limit signalling through the PI-3K-Akt signalling cascade.

EXPERIMENTAL

Antibodies and reagents

Rabbit anti-PKC δ , anti-PKC ϵ , anti-PKC η , anti-PKC ι , anti-PKC ζ and mouse anti-PKC (MC5) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Anti-(phospho-Akt), anti-(phospho-extracellular-signal-regulated protein kinase) and anti-(phospho-p70^{S6K}) antibodies were purchased from New England Biolabs (Beverly, MA, U.S.A.). Monoclonal anti-HA was a gift from Dr Bing Su (University of Texas M. D. Anderson Cancer Center, Houston, TX, U.S.A.). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG and HRP-conjugated goat anti-mouse IgG were purchased from Bio-Rad (Hercules, CA, U.S.A.). HRP-conjugated Protein A was obtained from Amersham (Arlington Heights, IL, U.S.A.). Protein-A-conjugated Sepharose 4B was purchased from Pharmacia Biotech (Piscataway, NJ, U.S.A.). Ro-31-8220, GF109203X and LY294002 were purchased from Calbiochem (La Jolla, CA, U.S.A.). Wortmannin and monoclonal anti-(epidermal growth factor receptor) antibody were obtained from Sigma (St Louis, MO, U.S.A.). HA-epitope tagged wild-type Akt was a gift from Dr Julian Downward (London, U.K.). cDNA plasmids of PKC ζ and PKC λ/ι were purchased from Invitrogen (Carlsbad, CA, U.S.A.). For the construction of a kinase-deficient dominant-negative (dn) PKC ζ K275W mutant, site-directed mutagenesis of the full-length PKC ζ cDNA was performed as described previously [17]. 1-Oleoyl-2-hydroxy-*sn*-glycero-3-phosphate (lysophosphatidic acid) 18:1 (LPA 18:1) was purchased from Avanti Polar Lipids (Alabaster, AL, U.S.A.).

Cell lines

Human breast cancer cell lines MDA-MB-468 (University of Texas M. D. Anderson Cancer Center, Houston, TX, U.S.A.) and BT-549 from American Type Culture Collection (Manassas, VA, U.S.A.) were cultured in RPMI 1640 medium (Gibco, Grand Island, NY, U.S.A.) containing 1% (w/v) penicillin/streptomycin (Gibco), 2 mM L-glutamine (Gibco) and 10% (v/v) fetal bovine serum (Sigma) at 37 °C in a humidified atmosphere.

Transient transfection

Cells were transiently transfected with various combinations of the expression vectors by FugeneTM 6 Transfection Reagent (Boehringer Mannheim Inc., Indianapolis, IN, U.S.A.) as recommended by the manufacturer.

Cell lysis, immunoprecipitation and immunoblotting

After transfection, cells were serum-starved overnight before stimulation with epidermal growth factor (EGF) (20 ng/ml) or LPA (5 μ M) for 10 min. Inhibition of PKC activity was performed by treatment of the cells with different doses of Ro-31-8220 or GF109203X for 1 h before cell harvest. PI-3K activity was inhibited by pretreatment of the cells with LY294002 or wortmannin for 1 h before stimulation. Cells were washed twice with cold PBS and lysed in ice-cold lysis buffer [50 mM Hepes (pH 7.4)/150 mM NaCl/1 mM EGTA/100 mM NaF/1.5 mM MgCl₂/10 mM sodium pyrophosphate/1% (v/v) Triton X-100/1 mM Na₃VO₄/10% (v/v) glycerol/1 mM PMSF/10 μ g/ml aprotinin]. Cellular protein concentration was determined by

bicinchoninic acid reaction (Pierce, Rockford, IL, U.S.A.). For immunoprecipitation, detergent lysates were incubated with 1 μ g of anti-HA mAb (monoclonal antibody) at 4 °C for 2 h. Immune complexes were captured by Protein A-Sepharose beads. Immunoprecipitates were washed with IP wash buffer [0.5% (v/v) Triton X-100/0.5% (v/v) Nonidet P40/10 mM Tris/HCl (pH 7.4)/150 mM NaCl/1 mM EDTA/1 mM EGTA/1 mM Na₃VO₄/1 mM PMSF]. Proteins were separated by SDS/PAGE and transferred to Immobilon membranes (Millipore, Bedford, MA, U.S.A.). Membranes were blocked with 5% (w/v) BSA for 1 h and then incubated for 2 h at room temperature or overnight at 4 °C with anti-(phospho-Akt) (1:1000 dilution), total Akt antibody (1:1000 dilution), anti-(phospho-p70^{S6K}) (1:1000 dilution) or PKC isoform antibodies (0.5 μ g/ml). Membranes were washed in TBS-T buffer [10 mM Tris/HCl (pH 7.4)/150 mM NaCl/0.1% (v/v) Tween 20] and incubated with HRP-conjugated goat anti-mouse IgG or goat anti-rabbit IgG (1:2500 dilution) for 1 h at room temperature. Proteins were detected by enhanced chemiluminescence (ECL^{*}; Amersham).

Akt kinase activity

Cells were lysed in 1% (v/v) Nonidet P40 lysis buffer. Cell lysates, normalized for protein levels (bicinchoninic acid assay), were immunoprecipitated with anti-(total Akt) and Protein A-Sepharose. Akt kinase activity was determined as described [4].

RESULTS

Expression of PKC isoforms in breast cancer cell lines MDA-MB-468 and BT-549

To investigate a potential role of PKC in regulating the PI-3K signalling pathway in breast cancer cells, we first assessed the expression of different PKC isoforms in MDA-MB-468 and BT-549 breast cancer cell lines. Both cell lines expressed the δ , ϵ , η , ζ and λ/ι isoforms of PKC, with MDA-MB-468 cells having higher levels of each of these isoforms than BT-549 cells (Figure 1). Furthermore, the mAb MC-5, which recognizes all cPKC isoenzymes, failed to detect cPKC expression in MDA-MB-468 total cell lysates. Ready detection of cPKC in BT-549 cells suggests that MDA-MB-468 cells express low to absent levels of conventional PKC isoforms.

Inhibition of aPKC increases Akt phosphorylation and activity

To explore the regulatory effects of PKC on Akt, we assessed the effect of the PKC inhibitor Ro-31-8220 on Akt phosphorylation in MDA-MB-468 breast cancer cells, given that MDA-MB-468 cells expressed nPKCs and aPKCs but lacked substantive expression of cPKCs (Figure 1). Ro-31-8220 is a potent PKC inhibitor, binding to PKC isoforms competitively with ATP [18]. As shown in Figure 2, Ro-31-8220 at 1–6 μ M significantly increased both Ser-473 and Thr-308 phosphorylation of Akt, reaching maximum effects at 6 μ M. In contrast, the expression level of Akt was not altered by Ro-31-8220. As predicted by the increase in Ser-473 and Thr-308 phosphorylation of Akt, Ro-31-8220 enhanced Akt enzyme activity as assessed in kinase assays *in vitro* with histone 2B as substrate.

Because Ro-31-8220 demonstrates little selectivity for specific PKC isoforms [18] and might inhibit other kinases, this result raised the question of which subtype(s) of PKC could contribute to the regulation of Akt activity. As little or no cPKC is expressed in MDA-MB-468 cells, the effect of Ro-31-8220 on Akt phosphorylation and activation (Figure 2) is unlikely to be mediated by cPKCs.




Figure 1 Expression of PKC isoforms in BT-549 and MDA-MB-468 breast cancer cell lines

Cells were cultured and harvested as described in the Experimental section. Cells were lysed; proteins were then separated by SDS/PAGE and immunoblotted with mAb MC-5 (against cPKCs) or polyclonal rabbit anti-PKC δ , anti-PKC ϵ , anti-PKC η , anti-PKC ζ or anti-PKC λ/i antibodies. The same membranes were stripped and reprobed with anti-(β -actin) mAb to confirm equal loading of proteins. The immunoblots were detected with enhanced chemiluminescence reagents. The results shown are representative of three independent experiments.




Figure 2 Increase in Akt phosphorylation and activation by Ro-31-8220 in a dose-dependent manner

MDA-MB-468 cells were starved overnight, then treated with the indicated amounts of Ro-31-8220 or vehicle [0.1% (v/v) DMSO] for 1 h. Cells were lysed and the samples were processed for Western blotting with anti-(phospho-Ser-473) or anti-(phospho-Thr-308) antibodies. The same membranes were stripped and re-probed with anti-Akt antibody to detect the expression levels of Akt. For assessment of Akt kinase activity, cells treated with Ro-31-8220 were lysed and Akt kinase activity was determined as described in the Experimental section. The assay mixture was separated by SDS/PAGE [12% (w/v) gel] and 32 P-labelled product was detected by autoradiography. Results were quantified by densitometry and the value from untreated cells was taken as unity. The results shown are representative of at least four independent experiments.

To gain further insight into the relative role of aPKCs and nPKCs in Akt regulation, we used GF109203X, which at a concentration of 0.2 μ M is sufficient to block approx. 90% of the kinase activity of cPKC and nPKC isoenzymes, and for aPKCs its IC_{50} is 6–10 μ M [19,20]. Incubation of MDA-MB-468 cells with GF109203X at 0.1, 1, 2, 5 and 10 μ M increased Akt phosphorylation at Thr-308 by 3.2-fold, 3.7-fold, 6.7-fold, 7.3-




Figure 3 GF109203X increases Akt phosphorylation

For dose-response studies, serum-starved MDA-MB-468 cells were incubated for 1 h with the indicated amounts of GF109203X. Cells were then lysed; proteins were then separated by SDS/PAGE and immunoblotted with anti-(phospho-Thr-308) (top panel) or anti-(phospho-Ser-473) (middle panel) antibodies. The membranes were stripped and reprobed with anti-Akt to confirm equal expression levels of Akt (bottom panel). Results were quantified by densitometry and the value from untreated cells was taken as unity. The results shown are representative of two independent experiments.

fold and 12.6-fold respectively; similar results were seen with Ser-473 (Figure 3). These results are most compatible with aPKCs' being major negative regulators of Akt. However, the concentration dependence of GF109203X also suggests that nPKC might contribute to the regulation of Akt phosphorylation and activity.

Activation of Akt by Ro-31-8220 is PI-3K-dependent

To determine whether activation of Akt by Ro-31-8220 was dependent on PI-3K activity, we pretreated MDA-MB-468 cells with PI-3K inhibitors LY294002 (1 μ M) or wortmannin (10 nM and 100 nM) for 1 h before incubation of the cells with Ro-31-8220 (4 μ M, 1 h). Western blot analysis with anti-(phospho-Ser-473) or anti-(phospho-Thr-308) antibodies demonstrated that inhibition of PI-3K activity inhibited Ro-31-8220-induced Akt phosphorylation and decreased basal Akt phosphorylation (Figure 4). Similar results were obtained when Akt enzyme activity was assessed (Figure 4). In contrast, pretreatment with rapamycin did not affect basal and Ro-31-8220-induced Akt phosphorylation and activation (Figure 4, lower panel), ruling out the involvement of the FRAP/mTOR (mammalian target of rapamycin) phosphatidylinositol kinase-related kinase, which is also sensitive to wortmannin and LY294002 [21]. When approximately 90% of basal Akt phosphorylation was inhibited by 1 μ M LY294002, as indicated in Figure 4 (upper panel), Ro-31-8220 induced a small but detectable increase in Akt phosphorylation, suggesting that a small PI-3K-independent effect of Ro-31-8220 might exist. However, the complete inhibition of Ro-31-8220-induced Akt phosphorylation and activation by 100 nM wortmannin indicates that most of the effect of Ro-31-8220 is dependent on PI-3K.

Stable association of PKC ζ and Akt in breast cancer cells

PKC ζ and Akt have been demonstrated to associate *in vitro* [22,23] and in intact cells [3,10] providing a potential mechanism for the effects of PKC inhibitors on Akt phosphorylation and activity. To investigate the possible functional link between aPKC isoforms and Akt in breast cancer cell lines, we examined the physical association of exogenous PKC ζ or PKC λ/i with Akt in BT-549 breast cancer cells, because BT-549 cells expressed lower levels of aPKCs than MDA-MB-468 cells (Figure 1). We co-transfected BT-549 cells with expression constructs encoding




Figure 4 PI-3K dependence of Ro-31-8220-induced Akt phosphorylation and activation

Serum-starved MDA-MB-468 cells were pretreated for 1 h with LY294002 (upper panel) or rapamycin or wortmannin (lower panel), then incubated for 1 h with 4 μ M Ro-31-8220. Cells were lysed; lysates were separated by SDS/PAGE [10% (w/v) gel], then immunoblotted with anti-(phospho-Ser-473) or anti-(phospho-Thr-308) antibodies. Equal loading of proteins was determined by assessing Akt levels with anti-Akt antibody. Equal amounts of cell lysates were subjected to Akt kinase assay as described in the Experimental section. 32 P-labelled products were separated by SDS/PAGE [12% (w/v) gel] and detected by autoradiography. Results were quantified by densitometry and the value from untreated cells was taken as unity. The results shown are representative of three independent experiments.

V5-tagged PKC ζ or V5-tagged PKC λ/ι with a construct encoding HA-Akt and then assessed co-immunoprecipitation of the transfected PKC with Akt. As demonstrated in Figure 5 (top panel), the exogenous PKC ζ was readily detected in Akt immunoprecipitates. PKC λ/ι was present in Akt immunoprecipitates but at lower levels than PKC ζ despite similar levels of expression of PKC λ/ι , PKC ζ and Akt in each transfection. Strikingly, EGF increased the ability to detect PKC ζ in Akt immunoprecipitates approx. 5-fold, indicating that the interaction between these mediators was stabilized by activation of the EGF receptor (Figure 5, middle panel). Next we evaluated the ability of endogenous PKC ζ and Akt to interact in breast cancer cells. As illustrated in Figure 5 (bottom panel), an EGF-dependent binding of endogenous PKC ζ with Akt was readily observed in BT-549 cells, suggesting a direct association-mediated interaction of the two signalling proteins in intact cells. Thus the α PKCs PKC ζ and, to a smaller extent, PKC λ/ι bind Akt, a process that is increased by the activation of cells by EGF. This is in contrast with a previous report that did not assess the interaction of PKC λ/ι with Akt and demonstrated a growth-factor-dependent dissociation of PKC ζ and Akt in transfected cells [10].

Wild-type PKC ζ , but not dn PKC ζ , decreases EGF-induced Akt phosphorylation at Ser-473 and Thr-308

Phosphorylation of Akt at Ser-473 and Thr-308, which is indicative of Akt activation [4,24], was used to assess whether the




Figure 5 Co-immunoprecipitation of PKC ζ with Akt

Top panel: BT-549 cells were cultured in a 60 mm dish until 80% confluent; they were then co-transfected with HA-Akt and V5-PKC ζ or V5-PKC λ/ι at a ratio of 1:3 as described in the Experimental section, to ensure that all HA-Akt-containing cells also expressed PKC ζ . Co-transfection of HA-Akt with empty vector (pCDNA3.1 GS) was performed as a control. At 24 h after transfection, cells were serum-starved overnight. Cells were lysed and cell lysates were subjected to immunoprecipitation (IP) with anti-HA mAb and subsequent immunoblotting (IB) with anti-V5 antibody. Equal loading of proteins was detected with anti-HA mAb. The transfection efficiency of PKC ζ or PKC λ/ι was confirmed by immunoblotting whole cell lysates with anti-V5 antibody. Middle panel: BT-549 cells were co-transfected with HA-Akt and V5-PKC ζ at a 1:3 ratio. After transfection, cells were serum-starved overnight followed by 10 min of stimulation with EGF (20 ng/ml) or no stimulation before lysis. HA-Akt was immunoprecipitated (IP) from cell lysates with anti-HA mAb. The presence of PKC ζ in the immunoprecipitates was detected by immunoblotting (IB) with anti-V5 antibody, as indicated. The same membrane was stripped and reprobed with anti-HA mAb to confirm equal protein loading. Whole cell lysates were evaluated for expression of V5-PKC ζ with anti-V5 mAb antibody. Bottom panel: endogenous Akt was immunoprecipitated (IP) with anti-Akt antibody from 500 μ g of BT-549 cell lysate either untreated or treated with EGF (20 ng/ml) for 10 min. The presence of endogenous PKC ζ was detected by immunoblotting (IB) with anti-PKC ζ antibody. Rabbit anti-mouse (RAM) antibody was used as a negative control in the experiment. The results shown are representative of three independent experiments.

physical interaction of PKC ζ with Akt altered Akt activity. As shown in Figure 6 (top panel), EGF treatment induced a modest increase in Akt phosphorylation at Ser-473 and Thr-308 in cells transfected with Akt. In contrast, a marked decrease in Akt




Figure 6 Akt phosphorylation induced by EGF or LPA is reversed by overexpression of wild-type PKC ζ , but not dn PKC ζ

The same co-transfection protocol was used as described in the legend to Figure 5 with either V5-PKC ζ (top panel) or dn V5-PKC ζ (middle panel). BT-549 cells were serum-starved overnight after transfection and were either left unstimulated or stimulated with EGF (20 ng/ml) for 10 min. Cells were lysed and HA-Akt was immunoprecipitated (IP) from the cell lysates by anti-

phosphorylation was observed in EGF-treated cells co-transfected with HA-Akt and wild-type PKC ζ . The expression of exogenous PKC ζ and Akt without altering the ability of EGF to activate the EGF receptor was determined by Western blotting of whole cell lysate with phosphotyrosine antibody as indicated in Figure 6 (top panel).

Expression of PKC ζ had little effect on basal Akt phosphorylation (Figure 6, top panel), potentially arguing that PKC ζ must be activated as a consequence of PI-3K for its activity to be manifest. To clarify this issue, we exploited dn PKC ζ , which has the critical lysine residue at the ATP-binding site replaced by tryptophan, resulting in a kinase-defective mutant [17], to inhibit the activity of endogenous PKC ζ . As illustrated in Figure 6 (middle panel), an approx. 3-fold increase in Akt phosphorylation at both Thr-308 and Ser-473 was observed in MDA-MB-468 cells co-expressing dn PKC ζ and HA-Akt, suggesting that inhibition of PKC ζ activity limited its effect on Akt phosphorylation. In addition, no decrease in Akt phosphorylation was observed in EGF-treated cells transfected with dn PKC ζ , compared with an empty vector control (Figure 6, middle panel). Equal transfection efficiency of dn PKC ζ was determined by Western blotting of cell lysate with anti-V5 antibody (results not shown). Thus wild-type PKC ζ , but not dn PKC ζ , limits the EGF-induced increase in Akt phosphorylation, which is compatible with the effect of Ro-31-8220 on Akt phosphorylation (Figures 2 and 3) being due to the inhibition of endogenous PKC ζ .

Wild-type PKC ζ decreases LPA-induced Akt phosphorylation

LPA is a bioactive lipid exhibiting potent growth factor activity; it induces multiple biological responses in breast cancer cells [25]. In addition, LPA can induce a PI-3K-dependent activation of PKC ζ and Akt through membrane-anchored G-protein-coupled receptors [26]. To determine whether the ability of PKC ζ to limit the activation of Akt can be generalized to multiple growth factors and G-protein-coupled receptors as well as tyrosine-kinase-linked receptors, we co-transfected MDA-MB-468 breast cancer cells with empty vector or wild-type PKC ζ with HA-Akt, and then treated cells for 10 min with 5 μ M LPA. Western blot analysis with the anti-(phospho-Ser-473) antibody indicated that LPA induced a 2.2-fold increase in Akt phosphorylation over control levels (Figure 6, bottom panel). Co-transfection of wild-type PKC ζ severely curtailed LPA-induced Akt phosphorylation without altering basal Akt phosphorylation (Figure 6, bottom panel). The ability of LPA to activate extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) in cells expressing exogenous PKC ζ and Akt was determined by Western blotting with anti-(phospho-ERK) antibody (Figure 6, bottom panel). Taken together, these results suggest that PKC ζ negatively

regulates Akt phosphorylation. The immunoprecipitates were separated by SDS/PAGE [8% (w/v) gel] and immunoblotted (IB) with rabbit anti-(phospho-Ser-473) or anti-(phospho-Thr-308) antibodies. Equal loading of proteins and equal transfection efficiency were detected as indicated previously. Phosphorylation of the EGF receptor was examined by Western blotting of whole cell lysate with anti-phosphotyrosine mAb (top panel). Results were quantified by densitometry and the value from empty-vector-transfected and untreated cells was taken as unity. Bottom panel: equal amounts of HA-Akt were immunoprecipitated (IP) from lysates from MDA-MB-468 cells co-transfected with either empty vector or V5-PKC ζ with HA-Akt, then either unstimulated or stimulated with LPA (5 μ M) for 10 min as indicated. Phosphorylation of HA-Akt was detected by immunoblotting the immunoprecipitates with anti-(phospho-Ser-473) polyclonal antibody; the densitometry is presented as a histogram. The phosphorylation of ERK1 and ERK2 was examined by Western blotting of cell lysate with anti-(phospho-ERK) antibody. Values are means \pm S.D. for three independent experiments.




Figure 7 Ro-31-8220-induced phosphorylation of p70^{S6K} at Thr-389

BT-549 cells were starved overnight and then treated with Ro-31-8220 at 4 μ M for 1 h. Cells were lysed; lysates were subjected to Western blotting with anti-(phospho-Ser-473) (Akt) or anti-(phospho-Thr-389) (p70^{S6K}) antibodies. The membrane was stripped and re-probed with anti-Akt or anti-p70^{S6K} antibodies to indicate that the levels of Akt and p70^{S6K} proteins were not changed by the treatment. Results were quantified by densitometry as described above. The results shown are representative of three independent experiments.

regulates Akt phosphorylation in a growth-factor-dependent manner.

Ro-31-8220 increases phosphorylation of Thr-389 on p70^{S6K}

Phosphorylation of Thr-389 in the linker domain between catalytic and autoinhibitory domains is obligatory for p70^{S6K} activity, whereas phosphorylation on sites located within the C-terminal autoinhibitory domain or the catalytic domain by FRAP/RAFT/mTOR, p38, PDK1 and possibly other kinases modulates the effect of phosphorylation of Thr-389 [27,28]. To determine whether the increased Akt activity associated with PKC inhibition was transmitted through the PI-3K/Akt signalling cascade, we assessed the effect of Ro-31-8220 on the phosphorylation of Thr-389 in p70^{S6K}. As indicated in Figure 7, Ro-31-8220 (4 μ M, 1 h) increased Akt phosphorylation on Ser-473 in BT-549 cells concomitantly with Thr-389 in p70^{S6K}, which is consistent with increased signalling through the PI-3K/Akt signalling cascade. Again, the PKC inhibitor Ro-31-8220 did not change expression levels of Akt and p70^{S6K}.

DISCUSSION

The production of three phosphorylated phosphatidylinositols by PI-3K results in the activation and recruitment to the membrane of a subpopulation of PH-domain-containing proteins [29]. In addition, three phosphorylated phosphatidylinositols bind to and activate a number of proteins containing C2 domains, such as the PTEN tumour suppressor gene product, some phosphatidylinositol kinases (not PI-3K) and nPKCs and cPKCs, but not aPKCs, which lack the C2 domain found in other PKCs [29–31]. The aPKCs are regulated by PI-3K through binding to PDK1 [32] and a PDK1-mediated phosphorylation of a negative regulatory site in the activation loop of aPKCs [32,33]. The role of each of the PI-3K targets in the positive or negative regulation of the flow of signals through the PI-3K pathway is only beginning to be elucidated. The difficulty in analysing the integration of signals through the PI-3K cascade is magnified when cross-talk between multiple signalling pathways is taken into account.

Most studies of the PI-3K pathway have focused on the positive flow of signals through the PI-3K signalling cascade contributing to cell survival, proliferation and differentiation through Akt, Ilk, PDK1, Tec kinases and their downstream targets Bad, p70^{S6K}, caspase 9, forkhead and GSK3 α/β [2,3,34,35]. However, the recent discovery that the PTEN tumour suppressor gene product, implicated in tumorigenesis in multiple cell lineages and through germline mutations in the Cowden's breast cancer predisposition syndrome, specifically dephosphorylates the same 3' site in the inositol ring that is phosphorylated by PI-3K has focused attention on the negative regulation of this pathway [36,37]. In addition to PTEN, SHIP, by dephosphorylating the 5' site on the inositol ring of PtdIns(3,4,5)P₃, also seems to act as a negative regulator of signalling through the PI-3K pathway [38–40].

Multiple PKC family members and in particular aPKCs, including PKC ζ and PKC λ/l , are activated as a consequence of stimulation of PI-3K activity by many different growth factor receptors [32,41]. The present studies indicate that the aPKCs, particularly PKC ζ , participate in a negative feedback loop initiated by the activation of PI-3K by EGF and LPA and the subsequent activation of PKC ζ , which decreases the phosphorylation and activity of Akt. This activity of PKC ζ is transmitted through the PI-3K signalling cascade as a decrease in activation of p70^{S6K}. Because PKC ζ and p70^{S6K} can form a physical complex [42], PKC ζ might affect p70^{S6K} activity by several mechanisms. The results linking p70^{S6K} phosphorylation to Akt and PKC ζ extend a previous study that suggested that PKC ζ could decrease the ability of PDGF (platelet-derived growth factor) to activate Akt and transmit signals to GSK3 α [10]. The consequence of the feedback loop activated by PKC ζ is not clear. Although, as mentioned above, PKC ζ decreases signal transduction through PI-3K and Akt to p70^{S6K} and GSK3 α , which would be expected to decrease cellular proliferation and viability, PKC and probably PKC ζ also alter the phosphorylation of Bad [43], which would be predicted to increase cell survival. Thus the outcome of PI-3K-induced activation of PKC ζ probably depends on the intracellular machinery of the cell stimulated, the particular ligand activating the cell and the network of signalling cascades activated.

The mechanism(s) by which PKC ζ regulates the phosphorylation and activation of Akt also seem complex. PKC ζ interacts physically with Akt (Figure 5) [10,22,23], suggesting that Akt might be a direct target for phosphorylation by PKC ζ . Intriguingly, the effects of growth factors on this association might be quite different, depending on the receptor activated or the cell stimulated, because we have demonstrated that EGF markedly increases the association of PKC ζ with Akt in breast cancer cells (Figure 5), whereas PDGF has been reported to dissociate PKC ζ and Akt in Cos cells [10]. Our studies with inhibitors of PI-3K indicate that the effects of PKC ζ on Akt phosphorylation exhibit both PI-3K-dependent and PI-3K-independent components. The PI-3K-dependent component might indicate, at least in part, a requirement for activation of PKC ζ by PI-3K through PDK1, because the overexpression of PKC ζ did not alter basal Akt phosphorylation but rather blocked EGF-dependent or LPA-dependent Akt phosphorylation and activation. Doornbos et al. [10] suggest that the effects of PKC ζ are directly on Akt and are independent of upstream mediators such as PI-3K or SHIP, because they are exhibited in cells transfected with a membrane-targeted and growth-factor-independent PI-3K. However, because membrane-targeted PI-3K remains subject to regulation by the p85 subunit [44], this fails to rule out the possibility that PKC ζ might directly or indirectly have effects upstream of Akt. Although the physical interaction between PKC ζ and Akt suggests that Akt might be a direct target of PKC ζ , it is not

known whether the PI-3K-independent effect of PKC ζ is solely on Akt directly or whether other signalling molecules such as adenylate cyclase [9] are involved. Thus it remains possible and even likely that PKC ζ mediates multiple effects on the PI-3K signalling cascade upstream of Akt, at Akt and probably downstream of Akt.

An obligatory role of the PTEN tumour suppressor gene in the action of PKC ζ and PKC inhibitors on the phosphorylation of Akt is eliminated by the observation that both of the breast cancer cell lines used in these studies lack functional PTEN owing to homozygous mutations in the PTEN gene sequence that result in a complete lack of detectable PTEN protein [37]. Similarly, an obligatory role for conventional PKC in the effects of the PKC inhibitors on Akt phosphorylation and activation seems to be eliminated by the failure of MDA-MB-468 cells to express detectable levels of conventional PKCs (Figure 1). Although a lack of conventional PKCs might be unusual, it is not entirely without precedent, because we have previously identified an interleukin-2-dependent cell line apparently lacking conventional PKC protein and enzyme activity [45].

The concentration dependence of the effects of the PKC inhibitor GF109203X, which inhibits cPKC and nPKC at nanomolar concentrations and aPKC at micromolar concentrations [18,20], suggests that aPKC might have a major role in the effects of the inhibitor Ro-31-8220, although a small but significant (approx. 3.2-fold) increase in Akt phosphorylation was observed with 0.1 μ M GF109203X, indicating the possible involvement of nPKC in the regulation. Although the effects of the inhibitors implicate aPKC, as with all kinase inhibitors GF109203X and Ro-31-8220 might inhibit other kinases. However, the observations with the PKC inhibitors, when combined with the ability of PKC ζ to bind Akt in a growth-factor-dependent manner and the ability of PKC ζ to decrease growth-factor-induced Akt phosphorylation and activation, implicates PKC ζ as a major regulator of Akt phosphorylation and activation.

In summary, we have demonstrated that Akt and PKC ζ physically associate in a growth-factor-dependent manner. This association results in a decrease in the phosphorylation and activity of Akt, which is transduced through the signalling cascade as a decrease in p70^{S6k} activation. Although PKC ζ interacts physically with Akt, potential additional interactions and cross-talk between aPKCs and the PI-3K signalling cascade at the level of PI-3K, SHIP or downstream substrates cannot be eliminated. Taken together, the results indicate that PI-3K-dependent activation of PKC ζ leads to a feedback inhibition of signalling through the PI-3K/Akt signalling cascade resulting in decreased Akt phosphorylation and activity, which in turn leads to decreased p70^{S6k} and GSK3 α functionality. The role of this negative feedback loop in the functional outcomes of PI-3K signalling probably represents a complex interplay of positive and negative signals initiated by the PI-3K cascade as well as other signalling cascades.

We thank Dr B. Su for kindly providing the 12CA5 mAb. This work was supported by a DAMD studentship (17-17-97-1) to M. M., and NIH grants CA82716 and CA64602 to G. B. M., Komen Foundation grant BCTR98-1 to G. B. M. and the University of Texas M. D. Anderson Cancer Center Support Core Grant CA 16672.

REFERENCES

- Coffer, P. J., Jin, J. and Woodgett, J. R. (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. *Biochem. J.* **335**, 1–13
- Yano, S., Tokumitsu, H. and Soderling, T. R. (1998) Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. *Nature (London)* **396**, 584–587
- Summers, S. A., Kao, A. W., Kohn, A. D., Backus, G. S., Roth, R. A., Pessin, J. E. and Birnbaum, M. J. (1999) The role of glycogen synthase kinase 3 β in insulin-stimulated glucose metabolism. *J. Biol. Chem.* **274**, 17934–17940
- Franke, T. F., Kaplan, D. R., Cantley, L. C. and Toker, A. (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* **275**, 665–668
- Conway, A. M., Rakhit, S., Pyne, S. and Pyne, N. J. (1999) Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. *Biochem. J.* **337**, 171–177
- Andjelicovic, M., Maira, S. M., Cron, P., Parker, P. J. and Hemmings, B. A. (1999) Domain swapping used to investigate the mechanism of protein kinase B regulation by 3-phosphoinositide-dependent protein kinase 1 and Ser-473 kinase. *Mol. Cell Biol.* **19**, 5061–5072
- Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F. and Hawkins, P. T. (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* **277**, 567–570
- Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P. and Alessi, D. R. (1999) PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. *Curr. Biol.* **9**, 393–404
- Sable, C. L., Filippa, N., Hemmings, B. and Van Obberghen, E. (1997) cAMP stimulates protein kinase B in a wortmannin-insensitive manner. *FEBS Lett.* **409**, 253–257
- Doorbos, R. P., Theelen, M., van der Hoeven, P. C., van Blitterswijk, W. J., Verkleij, A. J. and van Bergen en Henegouwen, P. M. (1999) Protein kinase C ζ is a negative regulator of protein kinase B activity. *J. Biol. Chem.* **274**, 8589–8596
- Martelli, A. M., Sang, N., Borgatti, P., Capitani, S. and Neri, L. M. (1999) Multiple biological responses activated by nuclear protein kinase C. *J. Cell. Biochem.* **74**, 499–521
- Borner, C., Ueffing, M., Jaken, S., Parker, P. J. and Weinstein, I. B. (1995) Two closely related isoforms of protein kinase C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms. *J. Biol. Chem.* **270**, 78–86
- Yoshiji, H., Kuriyama, S., Ways, D. K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M. and Fukui, H. (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. *Cancer Res.* **59**, 4413–4418
- Scaglione-Sewell, B., Abraham, C., Bissonnette, M., Skarosi, S. F., Hart, J., Davidson, N. O., Wali, R. K., Davis, B. H., Sitrin, M. and Brasitus, T. A. (1998) Decreased PKC- α expression increases cellular proliferation, decreases differentiation, and enhances the transformed phenotype of CaCo-2 cells. *Cancer Res.* **58**, 1074–1081
- Carlin, S., Yang, K. X., Donnelly, R. and Black, J. L. (1999) Protein kinase C isoforms in human airway smooth muscle cells: activation of PKC- ζ during proliferation. *Am. J. Physiol.* **276**, L506–L512
- Schonwasser, D. C., Marais, R. M., Marshall, C. J. and Parker, P. J. (1998) Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isoforms. *Mol. Cell Biol.* **18**, 790–798
- Kampfer, S., Hellbert, K., Villunger, A., Doppler, W., Baier, G., Grunicke, H. H. and Uberall, F. (1998) Transcriptional activation of c-fos by oncogenic Ha-Ras in mouse mammary epithelial cells requires the combined activities of PKC- λ , ϵ and ζ . *EMBO J.* **17**, 4046–4055
- Mochly-Rosen, D. and Kauvar, L. M. (1998) Modulating protein kinase C signal transduction. *Adv. Pharmacol.* **44**, 91–145
- Uberall, F., Hellbert, K., Kampfer, S., Maly, K., Villunger, A., Spitaler, M., Mwanjewe, J., Baier-Bitterlich, G., Baier, G. and Grunicke, H. H. (1999) Evidence that atypical protein kinase C- λ and atypical protein kinase C- ζ participate in Ras-mediated reorganization of the F-actin cytoskeleton. *J. Cell Biol.* **144**, 413–425
- Goekjian, P. G. and Jirousek, M. R. (1999) Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. *Curr. Med. Chem.* **6**, 877–903
- Kim, S., Jung, Y., Kim, D., Koh, H. and Chung, J. (2000) Extracellular zinc activates p70 S6 kinase through the phosphatidylinositol 3-kinase signaling pathway. *J. Biol. Chem.* **275**, 25979–25984
- Konishi, H., Kuroda, S. and Kikkawa, U. (1994) The pleckstrin homology domain of RAC protein kinase associates with the regulatory domain of protein kinase C ζ . *Biochem. Biophys. Res. Commun.* **205**, 1770–1775
- Konishi, H., Kuroda, S., Tanaka, M., Matsuzaki, H., Ono, Y., Kameyama, K., Haga, T. and Kikkawa, U. (1995) Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subtypes and $\beta\gamma$ subunits of G proteins. *Biochem. Biophys. Res. Commun.* **216**, 526–534
- Jiang, B. H., Aoki, M., Zheng, J. Z., Li, J. and Vogt, P. K. (1999) Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 2077–2081

- 25 Xu, Y., Fang, X. J., Casey, G. and Mills, G. B. (1995) Lysophospholipids activate ovarian and breast cancer cells. *Biochem. J.* **309**, 933–9340
- 26 Takeda, H., Malozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K. and Kasuga, M. (1999) PI 3-kinase γ and protein kinase C- ζ mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. *EMBO J.* **18**, 386–395
- 27 Peterson, R. T. and Schreiber, S. L. (1998) Translation control: connecting mitogens and the ribosome. *Curr. Biol.* **8**, R248–R250
- 28 Dennis, P. B., Pullen, N., Pearson, R. B., Kozma, S. C. and Thomas, G. (1998) Phosphorylation sites in the autoinhibitory domain participate in p70 (s6k) activation loop phosphorylation. *J. Biol. Chem.* **273**, 14845–14852
- 29 Wymann, M. P. and Pirolo, L. (1998) Structure and function of phosphoinositide 3-kinases. *Biochim. Biophys. Acta* **1436**, 127–150
- 30 Leever, S. J., Vanhaesebroeck, B. and Waterfield, M. D. (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. *Curr. Opin. Cell Biol.* **11**, 219–225
- 31 Bondeva, T., Pirolo, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R. and Wymann, M. P. (1998) Bifurcation of lipid and protein kinase signals of PI3K γ to the protein kinases PKB and MAPK. *Science* **282**, 293–296
- 32 Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P. and Parker, P. J. (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. *Science* **281**, 2042–2045
- 33 Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., Chen, C. S., Newton, A. C., Schaffhausen, B. S. and Toker, A. (1998) Regulation of protein kinase C ζ by PI 3-kinase and PDK-1. *Curr. Biol.* **8**, 1069–1077
- 34 Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S. and Reed, J. C. (1998) Regulation of cell death protease caspase-9 by phosphorylation. *Science* **282**, 1318–1321
- 35 Lu, Y., Cuevas, B., Gibson, S., Khan, H., LaPushin, R., Imboden, J. and Mills, G. B. (1998) Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. *J. Immunol.* **161**, 5404–5412
- 36 Ramaswamy, S., Nakamura, N., Vazquez, F., Batt, D. B., Perera, S., Roberts, T. M. and Sellers, W. R. (1999) Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 2110–2115
- 37 Lu, Y., Lin, Y. Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M. et al. (1999) The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. *Oncogene* **18**, 7034–7045
- 38 Liu, Q., Sasaki, T., Koziarzki, I., Wakeham, A., Itie, A., Dumont, D. J. and Penninger, J. M. (1999) SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. *Genes Dev.* **13**, 786–791
- 39 Hashimoto, A., Hirose, K., Okada, H., Kurosaki, T. and Iino, M. (1999) Inhibitory modulation of B cell receptor-mediated Ca^{2+} mobilization by Src homology 2 domain-containing inositol 5'-phosphatase (SHIP). *J. Biol. Chem.* **274**, 11203–11208
- 40 Aman, M. J., Lamkin, T. D., Okada, H., Kurosaki, T. and Ravichandran, K. S. (1998) The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. *J. Biol. Chem.* **273**, 33922–33928
- 41 Standaert, M. L., Bandyopadhyay, G., Sajan, M. P., Cong, L., Quon, M. J. and Farese, R. V. (1999) Okadaic acid activates atypical protein kinase C (ζ/λ) in rat and 3T3/L1 adipocytes. An apparent requirement for activation of Glut4 translocation and glucose transport. *J. Biol. Chem.* **274**, 14074–14078
- 42 Romanelli, A., Martin, K. A., Toker, A. and Blenis, J. (1999) p70 S6 kinase is regulated by protein kinase C ζ and participates in a phosphoinositide 3-kinase-regulated signalling complex. *Mol. Cell Biol.* **19**, 2921–2928
- 43 Tan, Y., Ruan, H., Demeter, M. R. and Comb, M. J. (1999) p90(RSK) blocks Bad-mediated cell death via a protein kinase C-dependent pathway. *J. Biol. Chem.* **274**, 34859–34867
- 44 Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M. A. and Williams, L. T. (1996) Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. *Mol. Cell Biol.* **16**, 4117–4127
- 45 Mills, G. B., Girard, P., Grinstein, S. and Gelfand, E. W. (1988) Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C. *Cell* **55**, 91–100

Received 3 April 2000/31 July 2000; accepted 20 September 2000